Key result
Adding plasma hs-CRP measurement to routine clinical evaluation significantly increased the proportion of hypertensive patients stratified into high or very high cardiovascular risk groups.
Why the study?
Does the addition of hs-CRP measurement to routine biochemistries improve cardiovascular risk stratification in hypertensive patients?
Cross-Sectional (n=1,817)
Yes
Does the addition of hs-CRP measurement to routine biochemistries improve cardiovascular risk stratification in hypertensive patients?
Absolute Event Rate: 72.7% vs 59.2%
p-value: p=<0.001
Adding hs-CRP to routine evaluation in hypertensive patients significantly increases the proportion identified as high or very high cardiovascular risk, potentially altering preventive management.
Should not yet change hypertension risk stratification; leaves open whether hs-CRP addition improves outcome prediction in prospective cohorts.
The Intensive/Initial Cardiovascular Examination Regarding Blood Pressure Levels: Evaluation of Risk Groups (ICEBERG) study focused on the impact of high-sensitivity C-reactive protein (hs-CRP) measurement on cardiovascular risk evaluation. The ICEBERG study comprised 2 subprotocols. Each subprotocol had 2 patient profiles: patients previously diagnosed with essential hypertension and under medical treatment and patients with systolic blood pressure 130 mm Hg or higher, or diastolic blood pressure 85 mm Hg or higher, with no treatment for at least 3 months before inclusion. Measurement of hs-CRP and cardiovascular risk stratification were performed according to European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines. A total of 1817 patients were analyzed. In 1 group, the percentage of patients in "high" plus "very high" added-risk groups increased from 59.2% to 72.7% when hs-CRP data were added to routine serum biochemistries. In another, the increase was from 66.9% to 77.9%, whereas in a third group, it changed from 65.1% to 77.2%. The use of plasma hs-CRP levels might help in stratifying hypertensive patients into specific risk groups and modifying preventive approaches.
No takes yet. Share an insight, caveat, or question.
Kozan et al. (2007) conducted a cross-sectional in Hypertension (n=1,817). High-sensitivity C-reactive protein (hs-CRP) measurement vs. Routine clinical evaluation without hs-CRP was evaluated on Proportion of patients stratified into high plus very high added cardiovascular risk groups (treated referral group) (p=<0.001). Adding plasma hs-CRP measurement to routine clinical evaluation significantly increased the proportion of hypertensive patients stratified into high or very high cardiovascular risk groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: